Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001185567 | SCV001351817 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-04-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001495350 | SCV001700030 | likely benign | Peutz-Jeghers syndrome | 2023-11-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001495350 | SCV002057296 | uncertain significance | Peutz-Jeghers syndrome | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001185567 | SCV002687441 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-12 | criteria provided, single submitter | clinical testing | The p.F298L variant (also known as c.894C>G), located in coding exon 7 of the STK11 gene, results from a C to G substitution at nucleotide position 894. The phenylalanine at codon 298 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and leucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |